Houston meeting kicks off collaboration to advance cancer research

March 10, 2005

HOUSTON - Researchers from The University of Texas M. D. Anderson Cancer Center and Imperial College London met here today to launch a joint initiative aimed at advancing scientific discovery of novel cancer therapies. The agreement builds upon professional relationships between clinicians and researchers at both institutions and represents another step forward in the global fight to eradicate cancer.

The collaboration agreement calls for the establishment of a research program focused on identifying new molecular targets for cancer diagnosis and treatments that the two institutions will carry out over the next few years. Both are internationally renowned for their commitment to and excellence in translational medicine, which drives pioneering cancer research from the laboratory to patient therapies at the bedside.

Sir Richard Sykes, Rector of Imperial College London, said, "Cancer research has long been a major focus at Imperial, and collaborations with such prestigious international partners as M. D. Anderson will help to further strengthen exploration of cancer treatments as a key part of Imperial's research strategy."

By working together, Imperial College and M. D. Anderson hope to maximize their strengths in basic science research and clinical programs, accelerating the speed of scientific discoveries. Specifically, M. D. Anderson will look for additional opportunities to identify promising new anticancer agents for clinical development and to investigate new methods for diagnosing and treating cancer. Imperial hopes to expand its range of research programs and further contribute to the improvement of healthcare globally.

According to John Mendelsohn, M.D., President of M. D. Anderson Cancer Center, the agreement unites the strengths of two premier institutions. "With the goal of making more rapid progress in cancer diagnosis and treatment, our collaboration will lead to greater insights into the biology of cancer, and help us take advantage of advances in genomics and proteomics to create new diagnostic tests and targeted therapies for cancer."

Both institutions have invested in technology transfer and collaborative applied research initiatives in order to bring research discoveries to the market for the benefit of cancer patients everywhere, Dr. Mendelsohn said.

This agreement, signed on December 15, 2004, is the first of its kind for M. D. Anderson with a world class institution in the United Kingdom and is funded in part by the Department for Trade and Industry's UK-Texas Bioscience Initiative, which aims to promote collaborative research and development in biosciences and related topics between researchers in the UK and the region around Houston, Texas.
-end-
About The University of Texas M. D. Anderson Cancer Centre
M. D. Anderson, a non-profit institution founded in 1941, has established an international reputation as one of the world's pre-eminent centres for cancer patient care, research, education and prevention. A multidisciplinary approach, and dedication to translational research, education and prevention are hallmarks of M. D. Anderson, which also holds the distinction of being designated by the National Cancer Institute (NCI) as one of the first three Comprehensive Cancer Centres in the United States. It has been ranked the number one cancer centre in the United States in four of the past five years by U.S. News & World Report's "America's Best Hospitals." M. D. Anderson has provided care for more than 600,000 cancer patients since 1944 and 70,000 in the last year alone. Its faculty currently hold more NCI research grants and grant dollars than any other academic centre in the U.S. In 2003, nearly 1,000 new patients from outside the U.S. came to M. D. Anderson for care. www.mdanderson.org

About Imperial College London
Consistently rated in the top three UK university institutions, Imperial College London is a world leading science-based university whose reputation for excellence in teaching and research attracts students (11,000) and staff (6,000) of the highest international quality. Innovative research at the College explores the interface between science, medicine, engineering and management and delivers practical solutions that enhance the quality of life and the environment - underpinned by a dynamic enterprise culture. Website: www.imperial.ac.uk

Imperial College London

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.